Christopher Scott Lathan, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Lung Neoplasms | 28 | 2023 | 13593 | 1.440 |
Why?
|
National Cancer Institute (U.S.) | 4 | 2024 | 300 | 1.110 |
Why?
|
Cancer Care Facilities | 2 | 2024 | 428 | 0.920 |
Why?
|
Community-Institutional Relations | 1 | 2024 | 209 | 0.810 |
Why?
|
Neoplasms | 17 | 2024 | 22390 | 0.680 |
Why?
|
Healthcare Disparities | 17 | 2024 | 3421 | 0.640 |
Why?
|
Vulnerable Populations | 2 | 2021 | 718 | 0.620 |
Why?
|
Early Detection of Cancer | 8 | 2023 | 3238 | 0.530 |
Why?
|
Oncogene Proteins | 3 | 2015 | 718 | 0.520 |
Why?
|
Awareness | 1 | 2019 | 653 | 0.470 |
Why?
|
Peritoneal Neoplasms | 1 | 2020 | 714 | 0.430 |
Why?
|
Protein-Tyrosine Kinases | 1 | 2020 | 2433 | 0.360 |
Why?
|
Pneumonectomy | 2 | 2008 | 1159 | 0.340 |
Why?
|
Attitude to Health | 3 | 2015 | 2025 | 0.320 |
Why?
|
Cost of Illness | 2 | 2016 | 1959 | 0.320 |
Why?
|
Communication | 3 | 2022 | 3908 | 0.310 |
Why?
|
Molecular Diagnostic Techniques | 1 | 2013 | 620 | 0.300 |
Why?
|
Nuclear Proteins | 4 | 2016 | 5803 | 0.300 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 6 | 2019 | 5434 | 0.290 |
Why?
|
Proto-Oncogene Proteins | 1 | 2020 | 4528 | 0.290 |
Why?
|
Smoking | 8 | 2023 | 9094 | 0.280 |
Why?
|
Medical Oncology | 6 | 2022 | 2350 | 0.280 |
Why?
|
Leukemia | 3 | 2024 | 1520 | 0.270 |
Why?
|
Physician-Patient Relations | 2 | 2019 | 3269 | 0.260 |
Why?
|
Physicians | 1 | 2023 | 4607 | 0.250 |
Why?
|
Quality of Life | 6 | 2022 | 13510 | 0.240 |
Why?
|
SEER Program | 8 | 2019 | 1473 | 0.230 |
Why?
|
Genetic Testing | 3 | 2014 | 3590 | 0.220 |
Why?
|
Chemoembolization, Therapeutic | 1 | 2024 | 128 | 0.210 |
Why?
|
Prostatic Neoplasms | 7 | 2023 | 11229 | 0.200 |
Why?
|
Clinical Trials as Topic | 6 | 2024 | 8055 | 0.200 |
Why?
|
Smoking Cessation | 3 | 2022 | 2084 | 0.200 |
Why?
|
Health Knowledge, Attitudes, Practice | 4 | 2018 | 4053 | 0.200 |
Why?
|
Humans | 66 | 2024 | 768887 | 0.190 |
Why?
|
United States | 24 | 2024 | 73180 | 0.180 |
Why?
|
American Cancer Society | 2 | 2017 | 69 | 0.180 |
Why?
|
Genetic Counseling | 1 | 2023 | 634 | 0.160 |
Why?
|
Eligibility Determination | 2 | 2024 | 421 | 0.160 |
Why?
|
Colorectal Neoplasms | 2 | 2016 | 6982 | 0.160 |
Why?
|
Proctoscopy | 1 | 2018 | 40 | 0.160 |
Why?
|
Medically Underserved Area | 1 | 2021 | 267 | 0.160 |
Why?
|
Hepatitis B | 1 | 2024 | 711 | 0.150 |
Why?
|
Patient Participation | 3 | 2018 | 1448 | 0.150 |
Why?
|
Insurance Coverage | 4 | 2024 | 1946 | 0.150 |
Why?
|
Middle Aged | 30 | 2024 | 223740 | 0.150 |
Why?
|
Male | 39 | 2024 | 365249 | 0.140 |
Why?
|
Patient Preference | 2 | 2022 | 947 | 0.130 |
Why?
|
Papillomavirus Infections | 2 | 2018 | 1640 | 0.130 |
Why?
|
Career Choice | 1 | 2022 | 769 | 0.130 |
Why?
|
Health Plan Implementation | 1 | 2019 | 338 | 0.130 |
Why?
|
Aged | 26 | 2024 | 171790 | 0.130 |
Why?
|
Carcinoma, Small Cell | 2 | 2008 | 419 | 0.120 |
Why?
|
Hospitals | 1 | 2008 | 3903 | 0.120 |
Why?
|
Gene Rearrangement | 1 | 2020 | 1148 | 0.120 |
Why?
|
Anus Neoplasms | 1 | 2018 | 336 | 0.120 |
Why?
|
Delivery of Health Care | 4 | 2023 | 5375 | 0.110 |
Why?
|
Female | 30 | 2024 | 397464 | 0.110 |
Why?
|
Fellowships and Scholarships | 1 | 2022 | 1134 | 0.110 |
Why?
|
Health Status Disparities | 2 | 2017 | 1886 | 0.110 |
Why?
|
Neutrophils | 2 | 2024 | 3785 | 0.110 |
Why?
|
Medicare Part B | 1 | 2014 | 117 | 0.110 |
Why?
|
Gastrointestinal Neoplasms | 1 | 2021 | 957 | 0.110 |
Why?
|
Health Services Needs and Demand | 1 | 2021 | 1407 | 0.110 |
Why?
|
Logistic Models | 7 | 2014 | 13317 | 0.110 |
Why?
|
Genes, erbB-1 | 1 | 2013 | 163 | 0.110 |
Why?
|
Carcinoma | 2 | 2016 | 2340 | 0.100 |
Why?
|
Clinical Laboratory Techniques | 1 | 2018 | 749 | 0.100 |
Why?
|
Professional-Patient Relations | 1 | 2017 | 725 | 0.100 |
Why?
|
Health Services Research | 2 | 2017 | 1818 | 0.100 |
Why?
|
Liver Transplantation | 1 | 2024 | 2403 | 0.100 |
Why?
|
Papillomavirus Vaccines | 1 | 2018 | 497 | 0.100 |
Why?
|
In Situ Hybridization, Fluorescence | 2 | 2015 | 2525 | 0.100 |
Why?
|
Carcinoma, Hepatocellular | 1 | 2024 | 2336 | 0.090 |
Why?
|
Protein Kinase Inhibitors | 3 | 2020 | 5707 | 0.090 |
Why?
|
Leukemia, Myeloid, Acute | 2 | 2024 | 3626 | 0.090 |
Why?
|
Influenza, Human | 1 | 2022 | 1541 | 0.090 |
Why?
|
Prevalence | 4 | 2023 | 15875 | 0.090 |
Why?
|
Health Education | 1 | 2017 | 1059 | 0.090 |
Why?
|
Oncogene Proteins, Fusion | 2 | 2016 | 1616 | 0.090 |
Why?
|
Cross-Sectional Studies | 5 | 2024 | 26384 | 0.090 |
Why?
|
Socioeconomic Factors | 4 | 2019 | 7860 | 0.090 |
Why?
|
Adult | 18 | 2024 | 223818 | 0.080 |
Why?
|
Massachusetts | 3 | 2024 | 8888 | 0.080 |
Why?
|
Mediastinal Neoplasms | 1 | 2012 | 403 | 0.080 |
Why?
|
Mutation | 4 | 2017 | 30266 | 0.080 |
Why?
|
Carcinoma, Pancreatic Ductal | 1 | 2020 | 1756 | 0.080 |
Why?
|
Laparoscopy | 1 | 2020 | 2055 | 0.080 |
Why?
|
Sexual Behavior | 1 | 2018 | 2200 | 0.080 |
Why?
|
Prejudice | 2 | 2012 | 574 | 0.080 |
Why?
|
Liver Neoplasms | 1 | 2024 | 4363 | 0.080 |
Why?
|
Neoplasm Proteins | 3 | 2015 | 3608 | 0.070 |
Why?
|
Leukocyte Count | 2 | 2024 | 1609 | 0.070 |
Why?
|
Retrospective Studies | 12 | 2024 | 81892 | 0.070 |
Why?
|
Medicaid | 3 | 2017 | 2843 | 0.070 |
Why?
|
Poverty | 1 | 2019 | 2720 | 0.070 |
Why?
|
Health Services Accessibility | 1 | 2024 | 5520 | 0.070 |
Why?
|
Geriatric Assessment | 1 | 2014 | 1422 | 0.070 |
Why?
|
Guidelines as Topic | 1 | 2013 | 1398 | 0.070 |
Why?
|
Spirituality | 2 | 2011 | 430 | 0.070 |
Why?
|
Mediastinoscopy | 1 | 2005 | 29 | 0.070 |
Why?
|
Aged, 80 and over | 8 | 2022 | 59738 | 0.060 |
Why?
|
Income | 1 | 2014 | 1878 | 0.060 |
Why?
|
Vaccination | 1 | 2018 | 3436 | 0.060 |
Why?
|
Medicare | 3 | 2019 | 6888 | 0.060 |
Why?
|
Health Care Reform | 1 | 2014 | 1262 | 0.060 |
Why?
|
Religion and Medicine | 1 | 2007 | 161 | 0.060 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 3 | 2019 | 11886 | 0.060 |
Why?
|
Patient Care Team | 1 | 2016 | 2527 | 0.060 |
Why?
|
Societies, Medical | 1 | 2017 | 3967 | 0.060 |
Why?
|
Thoracoscopy | 1 | 2005 | 186 | 0.060 |
Why?
|
Caregivers | 1 | 2017 | 2308 | 0.060 |
Why?
|
Neoplasm Staging | 4 | 2019 | 11262 | 0.060 |
Why?
|
Diagnosis, Differential | 1 | 2020 | 13020 | 0.060 |
Why?
|
Duffy Blood-Group System | 1 | 2024 | 61 | 0.060 |
Why?
|
Immunohistochemistry | 2 | 2015 | 11119 | 0.060 |
Why?
|
Radiography | 1 | 2015 | 6991 | 0.060 |
Why?
|
Receptor Protein-Tyrosine Kinases | 1 | 2011 | 1629 | 0.060 |
Why?
|
Social Class | 1 | 2012 | 2009 | 0.050 |
Why?
|
Pancreatic Neoplasms | 1 | 2020 | 5443 | 0.050 |
Why?
|
Health Policy | 1 | 2014 | 2700 | 0.050 |
Why?
|
Bilirubin | 1 | 2024 | 438 | 0.050 |
Why?
|
Estrogens, Conjugated (USP) | 1 | 2023 | 277 | 0.050 |
Why?
|
Mental Health Services | 1 | 2013 | 1732 | 0.050 |
Why?
|
Head and Neck Neoplasms | 1 | 2016 | 2931 | 0.050 |
Why?
|
Genomics | 2 | 2019 | 5928 | 0.050 |
Why?
|
Focus Groups | 2 | 2018 | 1461 | 0.050 |
Why?
|
Interviews as Topic | 3 | 2018 | 2742 | 0.050 |
Why?
|
Terminal Care | 2 | 2011 | 1772 | 0.050 |
Why?
|
Ablation Techniques | 1 | 2024 | 255 | 0.050 |
Why?
|
Boston | 3 | 2018 | 9375 | 0.050 |
Why?
|
Palliative Care | 2 | 2017 | 3644 | 0.040 |
Why?
|
Hepatectomy | 1 | 2024 | 588 | 0.040 |
Why?
|
Cohort Studies | 4 | 2015 | 41800 | 0.040 |
Why?
|
Bronchoscopy | 1 | 2005 | 914 | 0.040 |
Why?
|
Telemedicine | 1 | 2017 | 3109 | 0.040 |
Why?
|
Adenocarcinoma | 1 | 2017 | 6401 | 0.040 |
Why?
|
Risk Factors | 7 | 2017 | 74971 | 0.040 |
Why?
|
Advance Care Planning | 1 | 2007 | 698 | 0.040 |
Why?
|
Survival Rate | 3 | 2019 | 12873 | 0.040 |
Why?
|
BRCA2 Protein | 1 | 2023 | 803 | 0.040 |
Why?
|
Health Care Costs | 1 | 2011 | 3270 | 0.040 |
Why?
|
Ecosystem | 1 | 2022 | 494 | 0.040 |
Why?
|
Retreatment | 1 | 2019 | 600 | 0.040 |
Why?
|
Tennessee | 1 | 2017 | 123 | 0.040 |
Why?
|
HIV Infections | 1 | 2024 | 17589 | 0.040 |
Why?
|
Sex Factors | 3 | 2019 | 10641 | 0.030 |
Why?
|
Goals | 1 | 2022 | 716 | 0.030 |
Why?
|
BRCA1 Protein | 1 | 2023 | 1156 | 0.030 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2012 | 4064 | 0.030 |
Why?
|
Young Adult | 4 | 2018 | 60110 | 0.030 |
Why?
|
Biological Specimen Banks | 1 | 2022 | 789 | 0.030 |
Why?
|
Survival Analysis | 2 | 2005 | 10115 | 0.030 |
Why?
|
Adaptation, Psychological | 1 | 2007 | 2667 | 0.030 |
Why?
|
Patient Protection and Affordable Care Act | 2 | 2017 | 1189 | 0.030 |
Why?
|
Pancreatectomy | 1 | 2020 | 825 | 0.030 |
Why?
|
Kidney Function Tests | 1 | 2018 | 684 | 0.030 |
Why?
|
Risk Assessment | 3 | 2019 | 24330 | 0.030 |
Why?
|
Tomography, X-Ray Computed | 1 | 2019 | 20776 | 0.030 |
Why?
|
Referral and Consultation | 2 | 2021 | 3626 | 0.030 |
Why?
|
Community Health Centers | 1 | 2018 | 469 | 0.030 |
Why?
|
Gene Fusion | 1 | 2017 | 357 | 0.030 |
Why?
|
Multivariate Analysis | 3 | 2014 | 12093 | 0.030 |
Why?
|
Proportional Hazards Models | 2 | 2005 | 12563 | 0.030 |
Why?
|
Disease-Free Survival | 2 | 2016 | 6856 | 0.030 |
Why?
|
Structural Homology, Protein | 1 | 2013 | 86 | 0.030 |
Why?
|
Sulfonamides | 1 | 2023 | 1982 | 0.030 |
Why?
|
Depression | 1 | 2013 | 8240 | 0.030 |
Why?
|
Minority Health | 1 | 2014 | 79 | 0.030 |
Why?
|
Odds Ratio | 1 | 2005 | 9682 | 0.030 |
Why?
|
Acute Disease | 1 | 2024 | 7245 | 0.030 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2022 | 10397 | 0.030 |
Why?
|
Neutropenia | 1 | 2018 | 893 | 0.030 |
Why?
|
Models, Molecular | 2 | 2013 | 5404 | 0.030 |
Why?
|
Creatinine | 1 | 2018 | 1917 | 0.020 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2020 | 3554 | 0.020 |
Why?
|
Neck | 1 | 2016 | 736 | 0.020 |
Why?
|
Patient Acceptance of Health Care | 2 | 2018 | 3233 | 0.020 |
Why?
|
Social Identification | 1 | 2012 | 108 | 0.020 |
Why?
|
Mutagenesis, Insertional | 1 | 2013 | 662 | 0.020 |
Why?
|
Terminally Ill | 1 | 2013 | 240 | 0.020 |
Why?
|
Education, Medical, Graduate | 1 | 2022 | 2422 | 0.020 |
Why?
|
Minority Groups | 1 | 2017 | 1216 | 0.020 |
Why?
|
Age Factors | 2 | 2019 | 18454 | 0.020 |
Why?
|
Crystallography, X-Ray | 1 | 2013 | 1952 | 0.020 |
Why?
|
Artifacts | 1 | 2018 | 1942 | 0.020 |
Why?
|
Emigration and Immigration | 1 | 2012 | 407 | 0.020 |
Why?
|
Costs and Cost Analysis | 1 | 2014 | 1669 | 0.020 |
Why?
|
Pilot Projects | 1 | 2022 | 8742 | 0.020 |
Why?
|
Neoplasm Metastasis | 1 | 2019 | 4926 | 0.020 |
Why?
|
Prognosis | 3 | 2019 | 30044 | 0.020 |
Why?
|
Disease Management | 1 | 2019 | 2537 | 0.020 |
Why?
|
DNA, Neoplasm | 1 | 2013 | 1748 | 0.020 |
Why?
|
Needs Assessment | 1 | 2014 | 1142 | 0.020 |
Why?
|
Perception | 1 | 2014 | 1209 | 0.020 |
Why?
|
Forecasting | 1 | 2017 | 2946 | 0.020 |
Why?
|
Culture | 1 | 2012 | 623 | 0.020 |
Why?
|
Religion | 1 | 2011 | 376 | 0.020 |
Why?
|
Exons | 1 | 2013 | 2395 | 0.020 |
Why?
|
Molecular Targeted Therapy | 1 | 2019 | 2830 | 0.020 |
Why?
|
Drug Resistance, Neoplasm | 2 | 2013 | 5342 | 0.020 |
Why?
|
Qualitative Research | 1 | 2018 | 3143 | 0.020 |
Why?
|
Follow-Up Studies | 2 | 2019 | 39394 | 0.020 |
Why?
|
Quinazolines | 1 | 2013 | 1373 | 0.020 |
Why?
|
Combined Modality Therapy | 1 | 2019 | 8559 | 0.020 |
Why?
|
Antineoplastic Agents | 2 | 2024 | 13699 | 0.020 |
Why?
|
Incidence | 2 | 2017 | 21545 | 0.020 |
Why?
|
Protein Conformation | 1 | 2013 | 3956 | 0.020 |
Why?
|
Chromosome Aberrations | 1 | 2012 | 1780 | 0.020 |
Why?
|
Pastoral Care | 1 | 2007 | 72 | 0.020 |
Why?
|
Cell Line, Tumor | 2 | 2013 | 17174 | 0.020 |
Why?
|
Patient Selection | 1 | 2018 | 4265 | 0.020 |
Why?
|
Genetic Predisposition to Disease | 3 | 2012 | 18065 | 0.010 |
Why?
|
Regression Analysis | 1 | 2014 | 6346 | 0.010 |
Why?
|
Prospective Studies | 3 | 2014 | 54950 | 0.010 |
Why?
|
Survivors | 1 | 2014 | 2383 | 0.010 |
Why?
|
Genome, Human | 1 | 2017 | 4456 | 0.010 |
Why?
|
Lung | 1 | 2022 | 10097 | 0.010 |
Why?
|
Attitude to Death | 1 | 2007 | 401 | 0.010 |
Why?
|
Severity of Illness Index | 2 | 2014 | 15955 | 0.010 |
Why?
|
Family Health | 1 | 2008 | 1255 | 0.010 |
Why?
|
Population Surveillance | 1 | 2013 | 2597 | 0.010 |
Why?
|
Treatment Outcome | 3 | 2020 | 65485 | 0.010 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2005 | 640 | 0.010 |
Why?
|
Base Sequence | 1 | 2013 | 12430 | 0.010 |
Why?
|
Infant | 2 | 2016 | 36541 | 0.010 |
Why?
|
Amino Acid Sequence | 1 | 2013 | 13427 | 0.010 |
Why?
|
Health Expenditures | 1 | 2014 | 2396 | 0.010 |
Why?
|
Pandemics | 1 | 2022 | 8745 | 0.010 |
Why?
|
Kaplan-Meier Estimate | 1 | 2012 | 6546 | 0.010 |
Why?
|
Biomedical Research | 1 | 2017 | 3463 | 0.010 |
Why?
|
Child, Preschool | 2 | 2016 | 42684 | 0.010 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2005 | 878 | 0.010 |
Why?
|
Molecular Sequence Data | 1 | 2013 | 17629 | 0.010 |
Why?
|
Pyrazoles | 1 | 2011 | 2029 | 0.010 |
Why?
|
Practice Guidelines as Topic | 1 | 2017 | 7460 | 0.010 |
Why?
|
Quality of Health Care | 1 | 2014 | 4338 | 0.010 |
Why?
|
Pyridines | 1 | 2011 | 2896 | 0.010 |
Why?
|
Nurses | 1 | 2008 | 2501 | 0.010 |
Why?
|
Prostate-Specific Antigen | 1 | 2008 | 2487 | 0.010 |
Why?
|
Health Surveys | 1 | 2008 | 4055 | 0.010 |
Why?
|
Linear Models | 1 | 2007 | 5890 | 0.010 |
Why?
|
Longitudinal Studies | 1 | 2013 | 14795 | 0.010 |
Why?
|
Child | 2 | 2016 | 80969 | 0.010 |
Why?
|
Research Design | 1 | 2012 | 6213 | 0.010 |
Why?
|
Infant, Newborn | 1 | 2016 | 26394 | 0.010 |
Why?
|
Adolescent | 2 | 2016 | 89247 | 0.010 |
Why?
|
Mass Screening | 1 | 2008 | 5455 | 0.010 |
Why?
|
Signal Transduction | 1 | 2011 | 23652 | 0.000 |
Why?
|
Animals | 1 | 2014 | 169408 | 0.000 |
Why?
|